Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

2020509 citationsJournal Articlegreen Open Access

Authors

Partnerships for the goals

Published in: The Lancet Oncology

Volume 21, Issue 7, pp. 978-988

Field-Weighted Citation Impact: 49.61